Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
137
Views
2
CrossRef citations to date
0
Altmetric
Original Research

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer

Yan SongDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
,
Tao QuDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
,
Honggang ZhangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
,
Yongkun SunDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-3302-6023
ORCID Icon,
Chengxu CuiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
,
Yihebali ChiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
,
Wen ZhangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
,
Xingyuan WangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
&
Lin YangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence[email protected] [email protected]
 show all
Pages 6199-6205 | Published online: 07 Aug 2021

References

  • BrayF, FerlayJ, SoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. PMID: 30207593. doi:10.3322/caac.2149230207593
  • ZhengRS, SunKX, ZhangSW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41(1):19–28. PMID: 30678413. doi:10.3760/cma.j.issn.0253-3766.2019.01.00530678413
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon Cancer. Version 2; 2020. Available from: https://www.nccn.org/. Accessed July 31, 2021.
  • SunQ, ZhouJ, ZhangZ, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–1645. PMID: 25482937. doi:10.4161/15384047.2014.96408725482937
  • LiJ, QinS, XuRH, et al. Effect of fruquintinib vs. placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486–2496. PMID: 29946728. doi:10.1001/jama.2018.785529946728
  • Bekaii-SaabTS, OuFS, AhnDH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, Phase 2 study. Lancet Oncol. 2019;20(8):1070–1082. PMID: 31262657. doi:10.1016/S1470-2045(19)30272-431262657
  • KimJH, KimSY, KimKP, et al. Regorafenib-induced hypothyroidism as a predictive marker for improved survival in metastatic or unresectable colorectal cancer refractory to standard therapies: a Prospective Single-Center Study. Target Oncol. 2019;14(6):689–697. PMID: 31555963. doi:10.1007/s11523-019-00672-231555963
  • MakitaN, IiriT. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid. 2013;23(2):151–159. PMID: 23398161. doi:10.1089/thy.2012.045623398161
  • WongE, RosenLS, MulayM, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17(4):351–355. PMID: 17465866. doi:10.1089/thy.2006.030817465866
  • ScartozziM, GaliziaE, ChiorriniS, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20(2):227–230. PMID: 18842611. doi:10.1093/annonc/mdn63718842611
  • BonoP, RautiolaJ, UtriainenT, et al. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol. 2011;50(4):569–573. PMID: 21208033. doi:10.3109/0284186X.2010.54369621208033
  • BaiYX, QinSK, LiJ, et al. Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial. J Clin Oncol. 2020;38(15_suppl):abstr e16001. doi:10.1200/JCO.2020.38.15_suppl.e16001

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.